| |
Total population
|
No prior tocilizumab combination (n = 6821)
|
Ever prior tocilizumab combination (n = 448)
|
|---|
|
Baseline only
|
Baseline and follow-up
|
Baseline and follow-up
|
Baseline and follow-up
|
|---|
|
Age, per year
|
0.99 (0.98, 1.00)
|
1.04 (1.00, 1.08)
|
1.03 (0.99, 1.07)
|
1.03 (1.00, 1.06)
|
|
Male vs. female
|
0.82 (0.61, 1.11)
|
0.72 (0.24, 2.19)
|
1.01 (0.30, 3.37)
|
0.67 (0.30, 1.53)
|
|
Disease duration, per year
|
0.99 (0.98, 1.01)
|
1.04 (1.00, 1.07)
|
1.04 (1.00, 1.08)
|
1.05 (0.99, 1.10)
|
|
Serologic status*
|
|
Negative
|
Reference
| | | |
|
Positive
|
0.73 (0.57–0.93)
|
2.82 (0.46, 17.2)
|
0.38 (0.07, 2.18)
|
1.36 (0.27, 6.69)
|
|
Missing
|
0.50 (0.29–0.84)
|
9.58 (1.85, 49.7)
|
1.72 (0.39, 7.67)
|
0.99 (0.33, 3.03)
|
|
DMARD use**
|
|
csDMARD, baseline
|
0.48 (0.37–0.63)
|
–
|
–
|
–
|
|
TCZ combination
|
–
|
327 (80, 1343)
|
–
|
–
|
|
TNFi
|
–
|
0.21 (0.09, 0.49)
|
0.28 (0.11, 0.73)
|
0.08 (0.03, 0.21)
|
|
nonTNFi nonTCZ bDMARD
|
–
|
1.73 (0.86, 3.50)
|
2.70 (1.25, 5.85)
|
0.17 (0.07, 0.37)
|
|
Only csDMARD
|
–
|
0.94 (0.36, 2.47)
|
1.16 (0.40, 3.39)
|
2.76 (1.18, 6.47)
|
|
No DMARDs
|
–
|
0.05 (0.01, 0.16)
|
0.09 (0.03, 0.33)
|
0.02 (0, 0.12)
|
|
Glucocorticoid use
|
–
|
0.74 (0.39, 1.40)
|
0.91 (0.46, 1.78)
|
0.91 (0.46, 1.78)
|
|
CDAI, severe
|
–
|
Reference
|
Reference
|
Reference
|
|
Moderate
|
–
|
0.43 (0.23, 0.78)
|
0.41 (0.22, 0.79)
|
0.44 (0.17, 1.17)
|
|
Low
|
–
|
0.39 (0.21, 0.74)
|
0.40 (0.20, 0.79)
|
0.70 (0.29, 1.70)
|
|
Remission
|
–
|
0.17 (0.07, 0.42)
|
0.11 (0.04, 0.32)
|
0.53 (0.18, 1.52)
|
|
Comorbidities, count#
|
–
|
1.04 (0.98, 1.11)
|
1.09 (1.01, 1.18)
|
1.01 (0.92, 1.11)
|
- Notes: Odds ratios (95% confidence intervals). Baseline models used logistic regression. Models with follow-up data used mixed generalized linear regression
- TCZ tocilizumab; DMARD disease-modifying anti-rheumatic drug; csDMARDs conventional synthetic DMARDs; nonTNFi nonTCZ bDMARD includes all JAK inhibitors, abatacept, and rituximab
- ---Not considered at baseline or not significant in univariable screen so not considered in multivariable model or withheld from the model because of problems with convergence
- *Serologic status defined as a positive if either rheumatoid factor or anti-CCP antibody were ever positive up to the relevant reference point
- **Reference category for DMARD use is the non-use of a give DMARD
- #Comorbidities are noted in Table 1. Clinical disease activity index (CDAI) categories defined as remission (CDAI < 2.8), low (CDAI 2.9–10.0), moderate (CDAI 10.1–22.0), and high (CDAI > 22.1)
